FTXH First Trust Nasdaq Pharmaceuticals ETF
Quote as of Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 42.79 | Day Range | 42.20 – 42.55 |
| 52-Week Range | 27.30 – 42.87 | Volume | 159.26K |
| Avg Volume | 561.73K | AUM | $1.08B (Aug 27, 2026) |
| Expense Ratio | 0.60% | Yield (TTM) | 1.00% |
| NAV | 42.72 | Premium/Discount | -1.08% indicative |
| Inception | Sep 20, 2016 | Holdings | 51 |
| Issuer | First Trust | Exchange | NASDAQ |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 33738R837 | ISIN | US33738R8372 |
| Management | Not stated in source data | ||
About this ETF
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) operates as an exchange-traded fund. Its primary aim is to mirror the financial performance—both capital appreciation and income generation—of the Nasdaq US Smart Pharmaceuticals Index, prior to any fund-specific fees and expenses. To achieve this, the ETF endeavors to precisely replicate the constituents and their proportionate allocations within that index, striving for a performance correlation of at least 95%.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +8.22% | +21.23% | +19.11% | +28.29% | +52.56% | +16.24% | +9.72% | — | +7.59% |
| Total return | +8.22% | +21.51% | +19.62% | +28.84% | +54.63% | +17.96% | +11.25% | — | +8.94% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 26, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.60% | Annual cost of a $10,000 investment | $60.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 26, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 50 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Merck & Co., Inc. | MRK | 7.74% | 535.90K | $83.8M |
| 2 | Eli Lilly and Company | LLY | 7.16% | 62.88K | $77.6M |
| 3 | AbbVie Inc. | ABBV | 7.02% | 285.95K | $76.0M |
| 4 | Johnson & Johnson | JNJ | 6.74% | 267.19K | $73.0M |
| 5 | Bristol-Myers Squibb Company | BMY | 6.67% | 1.06M | $72.3M |
| 6 | Biogen Inc. | BIIB | 3.52% | 172.89K | $38.2M |
| 7 | Amgen Inc. | AMGN | 3.50% | 85.67K | $37.9M |
| 8 | Viatris Inc. | VTRS | 3.43% | 2.22M | $37.2M |
| 9 | Vertex Pharmaceuticals Incorporated | VRTX | 3.41% | 66.92K | $37.0M |
| 10 | Regeneron Pharmaceuticals, Inc. | REGN | 3.28% | 42.58K | $35.5M |
| 11 | Cardinal Health, Inc. | CAH | 3.18% | 144.99K | $34.5M |
| 12 | Pfizer Inc. | PFE | 3.16% | 1.20M | $34.3M |
| 13 | Gilead Sciences, Inc. | GILD | 3.06% | 222.59K | $33.1M |
| 14 | Incyte Corporation | INCY | 2.46% | 205.35K | $26.6M |
| 15 | Jazz Pharmaceuticals Plc | JAZZ | 2.41% | 100.39K | $26.1M |
| 16 | United Therapeutics Corporation | UTHR | 2.35% | 49.17K | $25.5M |
| 17 | Illumina, Inc. | ILMN | 2.28% | 110.01K | $24.8M |
| 18 | Zoetis Inc. | ZTS | 1.80% | 253.00K | $19.6M |
| 19 | Charles River Laboratories International, Inc. | CRL | 1.75% | 63.88K | $19.0M |
| 20 | Exelixis, Inc. | EXEL | 1.62% | 308.76K | $17.5M |
| 21 | Halozyme Therapeutics, Inc. | HALO | 1.52% | 150.56K | $16.5M |
| 22 | Medpace Holdings, Inc. | MEDP | 1.47% | 25.86K | $15.9M |
| 23 | Twist Bioscience Corporation | TWST | 1.36% | 97.34K | $14.7M |
| 24 | Moderna, Inc. | MRNA | 1.25% | 85.18K | $13.5M |
| 25 | 10X Genomics, Inc. (Class A) | TXG | 1.18% | 198.22K | $12.8M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 1.00% | Paid (last 12 months) | $0.4240 |
| Frequency | Quarterly | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Jun 25, 2026 | Last payment | $0.0920 (Jun 30, 2026) |
| Growth 1Y | -3.77% | Growth 3Y / 5Y (ann.) | -0.77% / +12.34% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 25, 2026 | Jun 25, 2026 | Jun 30, 2026 | $0.0920 |
| Mar 26, 2026 | Mar 26, 2026 | Mar 31, 2026 | $0.0573 |
| Dec 12, 2025 | Dec 12, 2025 | Dec 31, 2025 | $0.1294 |
| Sep 25, 2025 | Sep 25, 2025 | Sep 30, 2025 | $0.1453 |
| Jun 26, 2025 | Jun 26, 2025 | Jun 30, 2025 | $0.0892 |
| Mar 27, 2025 | Mar 27, 2025 | Mar 31, 2025 | $0.0992 |
| Dec 13, 2024 | Dec 13, 2024 | Dec 31, 2024 | $0.1304 |
| Sep 26, 2024 | Sep 26, 2024 | Sep 30, 2024 | $0.1218 |
| Jun 27, 2024 | Jun 27, 2024 | Jun 28, 2024 | $0.1284 |
| Mar 21, 2024 | Mar 22, 2024 | Mar 28, 2024 | $0.0676 |
| Dec 22, 2023 | Dec 26, 2023 | Dec 29, 2023 | $0.1232 |
| Sep 22, 2023 | Sep 25, 2023 | Sep 29, 2023 | $0.0725 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 17.75% / 17.11% | Sharpe 1Y / 3Y | 3.02 / 0.942 |
| Max drawdown 1Y / 3Y | -7.47% / -19.51% | Sortino 1Y | 5.48 |
| Beta vs S&P 500 (3Y) | 0.529 | Correlation vs S&P 500 (1Y) | 0.28 |
| Downside deviation 1Y | 9.79% | Risk-free rate used | 3.71% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 27, 2026. Formulas →
Liquidity
| Volume today | 159.26K | Average volume | 561.73K |
| AUM | $1.08B | Premium/Discount | -1.08% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $18.6M | +1.75% | $1.06B → $1.08B |
| 1 Week | $66.5M | +6.63% | $1.00B → $1.08B |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for FTXH
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.